The Global Peptic Ulcer Drugs Market is developing steadily as healthcare providers focus on effective treatment options for gastric, duodenal, and other ulcer-related conditions. Peptic ulcers can be associated with factors such as Helicobacter pylori infection and the use of nonsteroidal anti-inflammatory drugs, creating continued demand for appropriate therapies.

According to Market Research Future, the global market was valued at approximately USD 5.71 billion in 2025 and is projected to reach USD 9.74 billion by 2035, representing a CAGR of 5.48% during the forecast period.

Proton pump inhibitors remain an important part of the treatment landscape because of their established use in reducing stomach acid. At the same time, newer potassium-competitive acid blockers are gaining attention as pharmaceutical companies develop alternative approaches to acid suppression.

Growing awareness of digestive health and improvements in diagnosis are also supporting market development. Healthcare systems are increasingly emphasizing early identification and treatment of gastrointestinal conditions, which can encourage appropriate use of ulcer medications.

The market is also being influenced by changing distribution patterns. Hospital pharmacies and retail drug stores remain important channels, while online pharmacies are creating additional opportunities for convenient prescription fulfillment.

With continued pharmaceutical innovation, expanding healthcare access, and evolving treatment approaches, the global peptic ulcer drugs industry is expected to experience further development through the coming years.

Explore key developments shaping industry transformation:

Foam Dressing Market Trends

Cryo Electron Microscopy Market Growth

Electroretinography Market Demand

Feed Anticoccidials Market Volume

Plant Based API Market Forecast